Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays.
| Autor: | Grant-Klein RJ; 1Merck & Co., Inc., Kenilworth, New Jersey., Antonello J; 1Merck & Co., Inc., Kenilworth, New Jersey., Nichols R; 2Crozet BioPharma, Devens, Massachusetts., Dubey S; 1Merck & Co., Inc., Kenilworth, New Jersey., Simon JK; 1Merck & Co., Inc., Kenilworth, New Jersey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2021 Mar 29; Vol. 104 (5), pp. 1751-1754. Date of Electronic Publication: 2021 Mar 29. |
| DOI: | 10.4269/ajtmh.20-1055 |
| Abstrakt: | Gamma irradiation (GI) is included in the CDC guidance on inactivation procedures to render a group of select agents and toxins nonviable. The Ebola virus falls within this group because it potentially poses a severe threat to public health and safety. To evaluate the impact of GI at a target dose of 50 kGy on neutralizing antibody titers induced by the rVSVΔG-ZEBOV-GP vaccine (V920), we constructed a panel of 48 paired human serum samples (GI-treated versus non-GI-treated) from healthy participants selected from a phase 3 study of V920 (study V920-012; NCT02503202). Neutralizing antibody titers were determined using a validated plaque-reduction neutralization test. GI of sera from V920 recipients was associated with approximately 20% reduction in postvaccination neutralizing antibody titers. GI was not associated with any change in pre-vaccination neutralizing antibody titers. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|